Breaking News Instant updates and real-time market news.

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26

Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC

Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating Keytruda, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease. An interim analysis of the study's primary endpoint showed a complete response rate of 38.8 % at three months with Keytruda in patients whose disease was unresponsive to Bacillus Calmette-Guerin therapy, the current standard of care for this disease, and who were ineligible for or who refused to undergo radical cystectomy. The study's primary endpoints are CR rate and disease-free survival rate. The secondary endpoints include safety and duration of response. At the time of analysis, 72.5% of responding patients had an ongoing response and 25% experienced recurrent disease after CR. One patient who did not develop recurrent disease discontinued study treatment and started alternative therapy. No patients in Cohort A developed muscle invasive or metastatic urothelial carcinoma. Of the patients who achieved a CR at three months, 80% had a CR lasting for six months or longer, based on the Kaplan-Meier method. The median duration of response was not yet reached. The median follow-up was 14.0 months. The safety of Keytruda in KEYNOTE-057 was consistent with what has been seen in previous trials among patients treated with Keytruda monotherapy. Treatment-related adverse events occurred in 63.1% of patients. The most common TRAEs with an incidence of 5% or more were pruritus, fatigue, diarrhea, hypothyroidism and maculopapular rash. Grade 3-5 TRAEs occurred in 13 patients, and there was one treatment-related death, per investigator assessment.

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

MRK Merck
$72.34

0.12 (0.17%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/16/18
SBSH
10/16/18
NO CHANGE
Target $79
SBSH
Buy
Merck price target raised to $79 from $70 at Citi
Citi analyst Andrew Baum raised his price target for Merck (MRK) to $79 and reiterates a Buy rating on the shares. Following upward revisions to his Lynparza expectations, the analyst raised his earnings forecasts for Merck by 1%-9% over the 2021 to 2025 timeframe. The analyst anticipates that positive Lynparza first-line ovarian cancer trial will make Lynparza standard of care in wild type first-line ovarian cancer patients and leaving it well positioned to take market share in immuno-oncology based combinations post 2021. Baum also raised his price target for AstraZeneca (AZN), Merck's partner on Lynparza, to GBP 70 from GBP 62. He also has a Buy rating on those shares.
10/16/18
BTIG
10/16/18
INITIATION
Target $82
BTIG
Buy
Esperion initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Esperion (ESPR) with a Buy rating and a price target of $82, saying that with its development of bempedoic acid, or BA, to reduce cholesterol, the next key question is about the drug's safety. The analyst notes that while the data from Study 1 in May were disappointing, Study 2 readout in the next few weeks should have more answers. Shrader adds that the introduction of "non-stain" into the cholesterol market has already worked for Merck's (MRK) Zetia, and if BA is perceived well on its safety profile, it is "highly supportive" of its investment story.
10/11/18
FBCO
10/11/18
NO CHANGE
Target $81
FBCO
Outperform
Merck price target raised to $81 from $71 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Merck to $81 from $71, while reiterating an Outperform rating on the shares. While the shares have had a significant move this year, the analyst sees room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung setting. However, Divan also acknowledges longer-term investors remain concerned about how the company will navigate the Januvia patent expiration in mid-2022.

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

15:29
09/18/19
09/18
15:29
09/18/19
15:29
Hot Stocks
China's CATL to supply batteries for Daimler electric trucks »

Daimler Trucks &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$26.30

-0.4 (-1.50%)

15:29
09/18/19
09/18
15:29
09/18/19
15:29
Options
Bullish calendar call spread with a delta hedge in Devon Energy Corp »

Bullish calendar call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$26.32

-0.38 (-1.42%)

15:28
09/18/19
09/18
15:28
09/18/19
15:28
Options
- Bullish calendar call spread with a delta hedge in Devon Energy Corp »

- Bullish calendar call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$34.01

-0.27 (-0.79%)

15:27
09/18/19
09/18
15:27
09/18/19
15:27
Recommendations
Uber analyst commentary  »

Uber London operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$31.86

-0.51 (-1.58%)

15:25
09/18/19
09/18
15:25
09/18/19
15:25
Options
DXC Technology call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.69

-0.06 (-0.34%)

15:20
09/18/19
09/18
15:20
09/18/19
15:20
Hot Stocks
Shelton sees Cryoport becoming 'much broader' supply chain company »

Cryoport (CYRX) provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$158.78

0.66 (0.42%)

15:19
09/18/19
09/18
15:19
09/18/19
15:19
Hot Stocks
M&T Bank lowers prime lending rate to 5.0% from 5.25% »

Effective Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/18/19
09/18
15:17
09/18/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/18/19
09/18
15:16
09/18/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/18/19
09/18
15:15
09/18/19
15:15
General news
On the policy path: »

On the policy path: the…

SPY

SPDR S&P 500 ETF Trust

$299.06

-1.88 (-0.62%)

, SPX

S&P 500

$0.00

(0.00%)

15:11
09/18/19
09/18
15:11
09/18/19
15:11
General news
Fed Chair says not forecasting a recession »

Federal Reserve Chair…

SPY

SPDR S&P 500 ETF Trust

$299.06

-1.88 (-0.62%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.93 (-0.64%)

, SPX

S&P 500

$0.00

(0.00%)

15:07
09/18/19
09/18
15:07
09/18/19
15:07
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Powell doesn't think…

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.93 (-0.64%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$77.00

-2.7 (-3.39%)

, IAC

IAC

$230.15

-6.58 (-2.78%)

15:02
09/18/19
09/18
15:02
09/18/19
15:02
Hot Stocks
Match Group names Thomas Gaissmaier as Chief Human Resources Officer »

Match Group (MTCH)…

MTCH

Match Group

$77.00

-2.7 (-3.39%)

IAC

IAC

$230.15

-6.58 (-2.78%)

FOX

Fox Corp.

$32.24

-0.57 (-1.74%)

DIS

Disney

$135.88

-0.36 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 10

    Oct

  • 24

    Oct

SPY

SPDR S&P 500 ETF Trust

$298.51

-2.43 (-0.81%)

, SPX

S&P 500

$0.00

(0.00%)

15:01
09/18/19
09/18
15:01
09/18/19
15:01
General news
Powell says trade policy among things weighing on outlook »

Fed Chair Powell said the…

SPY

SPDR S&P 500 ETF Trust

$298.51

-2.43 (-0.81%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRD

Friedman Industries

$6.12

-0.04 (-0.65%)

15:01
09/18/19
09/18
15:01
09/18/19
15:01
Hot Stocks
Friedman Industries names Michael J. Taylor president, CEO »

Friedman Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
09/18/19
09/18
15:00
09/18/19
15:00
General news
More from Powell: this is a time of difficult judgments and disparate perspectives »

More from Powell: this is…

14:50
09/18/19
09/18
14:50
09/18/19
14:50
General news
Powell in Q&A: on whether this rate cut is still a "mid-cycle adjustment? »

Powell in Q&A: on…

MLHR

Herman Miller

$44.20

-0.3 (-0.67%)

14:49
09/18/19
09/18
14:49
09/18/19
14:49
Options
Herman Miller options imply 12.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

CYRX

Cryoport

$17.52

-0.23 (-1.30%)

14:47
09/18/19
09/18
14:47
09/18/19
14:47
Hot Stocks
Shelton sees 'bright future' ahead for Cryoport »

Cryoport (CYRX) provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$298.64

-2.3 (-0.76%)

, SPX

S&P 500

$0.00

(0.00%)

14:45
09/18/19
09/18
14:45
09/18/19
14:45
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Powell says FOMC has…

SPY

SPDR S&P 500 ETF Trust

$298.64

-2.3 (-0.76%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/18/19
09/18
14:45
09/18/19
14:45
General news
Chair Powell at the podium: Powell said the Fed cut rates again »

Chair Powell at the…

FITB

Fifth Third

$28.24

0.05 (0.18%)

14:42
09/18/19
09/18
14:42
09/18/19
14:42
Hot Stocks
Fifth Third decreases prime lending rate to 5% »

Fifth Third Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPY

SPDR S&P 500 ETF Trust

$298.73

-2.21 (-0.73%)

, SPX

S&P 500

$0.00

(0.00%)

14:41
09/18/19
09/18
14:41
09/18/19
14:41
General news
Fed Chair Powell says more rate cuts could be needed if economy weakens »

Asked if it remains his…

SPY

SPDR S&P 500 ETF Trust

$298.73

-2.21 (-0.73%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
09/18/19
09/18
14:40
09/18/19
14:40
General news
FOMC Forecast revisions »

FOMC Forecast revisions,…

SPY

SPDR S&P 500 ETF Trust

$298.88

-2.06 (-0.68%)

, SPX

S&P 500

$0.00

(0.00%)

14:38
09/18/19
09/18
14:38
09/18/19
14:38
General news
Fed Chair says additional signs seen of weakness abroad »

Federal Reserve Chair…

SPY

SPDR S&P 500 ETF Trust

$298.88

-2.06 (-0.68%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.